compounding pharmacy for tirzepatide FDA says pharmacies can keep making weight-loss med tirzepatide, now 1 and GIP therapy Drugmakers and pharmacists battle over

You should avoid naltrexone if you: Are taking opioid painkillers or anticipate needing painkillers (think: after an operation) Have recently stopped using opioids Are experiencing opioid withdrawal Have had a positive urine test for opioids Have failed a naloxone challenge test (used to check for opioid dependence) Naltrexone is also not recommended if you are allergic to it or any of its ingredients

Escobar-Chavez JJ, Merino-Sanjun V, Lpez-Cervantes M, Urban-Morlan Z, Pin-Segundo E, Quintanar-Guerrero D, et al

Cardiotoxicity Two small RCTs: Conflicting results, one showed no effect, one showed reduced cardiac events

This new analysis presented at ECO, focused on the difference in early cardiovascular events with semaglutide versus placebo from randomisation up to 12 months, with a focus on 3 and 6 months, to better understand the drugs effects, time to cardiovascular benefit, as well as predictors that might help identify patients at risk for early cardiovascular events

Informa UK Limited: 852861

15(6): p